Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424122 · ClinicalTrials.gov registry record · Phase 1
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT03424122 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 50 participants.
The verdict
NCT03424122, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.
Interventions
- DRUG Rituximab
- DRUG Ibrutinib
- DRUG Bendamustine
- DRUG Parsaclisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2022-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03424122
The ClinicalTrials.gov registry entry for NCT03424122 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT03424122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03424122 about?
NCT03424122 is a clinical study titled "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)". The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.
What is the current status of trial NCT03424122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-07-02. Estimated completion is 2022-06-27.
What interventions are being tested in trial NCT03424122?
The interventions under investigation include: Rituximab (DRUG), Ibrutinib (DRUG), Bendamustine (DRUG), Parsaclisib (DRUG).
Who is sponsoring clinical trial NCT03424122?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.